Drug Trial Radar · NCT04738487
Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)
Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
1,264
Actual
Start
Apr 7, 2021
Primary completion
Sep 5, 2024
Study completion Jan 27, 2026
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Feb 4, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers are looking for new ways to treat people with metastatic non-small cell lung cancer (NSCLC) that is PD-L1 positive. * Metastatic means cancer that has spread to other parts of the body. * PD-L1 positive means that PD-L1 is found on the cancer cells. PD-L1 is a protein that can help the cancer hide from the body's immune system. The goal of this study is to learn if people who receive vibostolimab and pembrolizumab live longer overall and without the cancer getting worse than people who receive pembrolizumab alone.
Conditions
- Lung Neoplasms
- Non-Small-Cell Lung Carcinoma
Interventions
Pembrolizumab/VibostolimabBiological
Coformulation of pembrolizumab (MK-3475) 200mg and vibostolimab (MK-7684) 200mg. Participants receive the coformulation by intravenous (IV) infusion every 3 weeks (Q3W) for up to 35 administrations (up to \~2 years).
PembrolizumabBiological
Participants receive 200 mg of pembrolizumab by intravenous (IV) infusion every 3 weeks (Q3W) for up to 35 administrations (up to \~2 years).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS) in Participants With PD-L1 TPS ≥50%Time frame: Up to ~39 months
Locations
188 sites in 23 countries. Site status is shown where the registry gives one.
Boca Raton Regional Hospital ( Site 0004)
Boca Raton, Florida
Illinois Cancer Care ( Site 0026)
Peoria, Illinois
Mercy Research - Cancer and Hematology Center ( Site 0032)
Springfield, Missouri
Mercy Research - David C. Pratt Cancer Center ( Site 0025)
St Louis, Missouri
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0022)
Mineola, New York
Memorial Sloan Kettering Cancer Center ( Site 0013)
New York, New York
Fox Chase Cancer Center-Hematology/Oncology ( Site 0030)
Philadelphia, Pennsylvania
Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA ( Site 0204)
Rio de Janeiro, Brazil
ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO-Pesquisa Clinica ( Site 0200)
São Paulo, Brazil
Núcleo de Pesquisa Clínica da Rede São Camilo ( Site 0207)
São Paulo, Brazil
Hospital São Carlos-Oncocentro Ce ( Site 0208)
Fortaleza, Ceará, Brazil
Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 0201)
Natal, Rio Grande do Norte, Brazil
ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 0206)
Ijuí, Rio Grande do Sul, Brazil
Irmandade da Santa Casa de Misericórdia de Porto Alegre-Centro de Pesquisa Novos Tratamentos em Cân
Porto Alegre, Rio Grande do Sul, Brazil
CEPEN - Centro de Pesquisa e Ensino em Oncologia de Santa Catarina ( Site 0209)
Florianópolis, Santa Catarina, Brazil
BC Cancer Victoria-Clinical Trials Unit ( Site 0107)
Victoria, British Columbia, Canada
Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0104)
Hamilton, Ontario, Canada
Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 0102)
Kingston, Ontario, Canada
Lakeridge Health ( Site 0106)
Oshawa, Ontario, Canada
Centre Intégré de Santé et de Services Sociaux (CISSS) de La-Centre intégré de cancérologie de Lava
Laval, Quebec, Canada
Bradford Hill Norte ( Site 0708)
Antofagasta, Chile
James Lind Centro de Investigacion del Cancer ( Site 0711)
Temuco, Araucania, Chile
CIDO SpA-Oncology ( Site 0707)
Temuco, Araucania, Chile
IC La Serena Research ( Site 0710)
La Serena, Coquimbo Region, Chile
Clínica Puerto Montt ( Site 0713)
Port Montt, Los Lagos Region, Chile
Oncocentro Valdivia ( Site 0715)
Valdivia, Los Ríos Region, Chile
Clinica Universidad Catolica del Maule-Oncology ( Site 0703)
Talca, Maule Region, Chile
Centro de Estudios Clínicos SAGA-CECSAGA ( Site 0712)
Santiago, Region M. de Santiago, Chile
Orlandi Oncologia ( Site 0700)
Santiago, Region M. de Santiago, Chile
FALP ( Site 0702)
Santiago, Region M. de Santiago, Chile
Bradfordhill ( Site 0701)
Santiago, Region M. de Santiago, Chile
The First Affiliated Hospital of Anhui Medical University ( Site 2022)
Hefei, Anhui, China
Anhui Provincil Hospital South District-Respiratory Medicine Dept ( Site 2017)
Hefei, Anhui, China
Cancer Hospital Chinese Academy of Medical Science-Oncology ( Site 2030)
Beijing, Beijing Municipality, China
Beijing Cancer hospital-intrathoratic deparmtment II ( Site 2001)
Beijing, Beijing Municipality, China
Beijing Cancer hospital-Thoracic Cancer Department A ( Site 2003)
Beijing, Beijing Municipality, China
Beijing Peking Union Medical College Hospital-pneumology department ( Site 2009)
Beijing, Beijing Municipality, China
Beijing Chest Hospital,Capital Medical University ( Site 2020)
Beijing, Beijing Municipality, China
Chongqing Cancer Hospital-Medical Oncology ( Site 2028)
Chongqing, Chongqing Municipality, China
Army Medical Center of People's Liberation Army-respiratory ( Site 2025)
Chongqing, Chongqing Municipality, China
Showing 40 of 188 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.